We have identified myelin basic protein (MBP) as a novel factor in brain that can bind Abeta and potently inhibit its assembly into fibrils. In light of this novel finding the overall hypothesis of this proposal is that defined fragments of MBP can regulate Abeta assembly and modulate its cytotoxic properties. This will provide the basis for developing novel and potent Abeta assembly inhibitors.